One-Third of Methadone Clinics Still Choose Punishment Over Treatment
Two years after SAMHSA loosened the rules, most clinics stopped treating patients as suspects. The ones that didn't don't get to call it treatment.
One-Third of Methadone Clinics Still Choose Punishment Over Treatment
On August 14, 2026, STAT News published survey results from 241 opioid treatment programs — about 10% of methadone clinics nationwide — two years into SAMHSA’s rewrite of the rules governing take-home doses and mandatory counseling. More than three-quarters of clinics report major changes. Retention rose an average of 17% at the three-month mark among clinics that adopted the new flexibilities. And about two-thirds of state opioid treatment authorities have dropped the practice of withholding medication as punishment for a missed appointment or a positive drug screen.
That last number is the one worth sitting with.
Withholding methadone from someone in withdrawal, as consequence for the very disease the medication treats, was never clinical judgment. It was a threat dressed up as a protocol.
For decades it was standard practice, alongside daily supervised dosing that made treatment functionally incompatible with holding a job, raising kids, or living more than a short drive from a clinic. The justification was always diversion risk — the fear that unsupervised doses would end up sold or misused. A Pew Charitable Trusts analysis released August 7 found that expanded take-home methadone has not increased diversion. The justification clinics used for 20-plus years to keep people driving to a dosing window every single morning didn’t hold up once someone actually checked.
So credit where it’s due: two-thirds of state authorities and three-quarters of surveyed clinics moved. AATOD president Mark Parrino calls it a real, durable culture shift, and the retention numbers back him up.
But Aaron Ferguson of Liberate Methadone, a person with lived experience of the system he’s now organizing against, called STAT’s framing “a misrepresentation of the field.” That’s not a minor quibble, and it shouldn’t be waved off as one clinic’s sour grapes. Surveys measure what programs say they changed, not what waiting rooms actually feel like at 6 a.m. A clinic can loosen its take-home policy on paper while a counselor still threatens a dose cut for a late arrival. The STAT number and Ferguson’s objection can both be true: the field moved, and the field’s own advocates don’t trust the number describing how far.
Which leaves the third that didn’t move, and the pocket of the two-thirds that only moved on paper. They’re not being cautious. There is no diversion data left to hide behind, and no retention data left to argue with — both now point the same direction. What’s left is a program that would rather keep the leverage than keep the patient. A clinic that still holds methadone over someone’s head isn’t managing risk. It’s running the counseling room like a parole office, and calling it care.
Sources Cited
- 01.B
- 02.ATake-Home Methadone Has Not Increased Medication DiversionThe Pew Charitable Trusts
Filed Under
treatmentpolicyMethadoneSAMHSA
Keep up with the reporting.
One email each morning with the stories that put days like this in context.
Continue reading
More from this section
Methadone's Rules Got Looser. Too Many Clinics Haven't Let Go.
Federal rules loosened methadone take-home and counseling requirements in 2024. STAT News reporting shows many clinics and states are still applying the old, rigid practices.
Treatment & RecoveryThe Thing That Gets People Into Treatment Was Never the Syringe. It Was the Person Handing It Over.
Syringe service program participants are roughly five times more likely to enter treatment. The psychology behind that number is about trust, not paraphernalia — and it's what federal cuts actually put at risk.
Treatment & RecoveryThere's Still No Pill for Cocaine. The Treatment That Works Pays You Instead — and Most States Won't Cover It.
There is no FDA-approved medication for cocaine or meth addiction. The one treatment with the strongest evidence base pays people for negative drug tests — and only five state Medicaid programs cover it.